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Abstract 
Background: General practitioners (GPs), community pharmacists and allergic rhinitis (AR) patients in Italy were sur-
veyed in order to gain insight from all three perspectives into the diagnosis, management and burden of AR in Italy.
Methods: General practitioners and pharmacists (n = 100 for each) were surveyed by telephone; questions related 
to overall practice and to last AR patient seen. Patients (n = 552) completed a questionnaire after visiting specialist 
allergy centres. Questions related to diagnosis and treatment, degree of everyday limitation from AR, and satisfaction 
with treatment. The data were analysed descriptively.
Results: Allergic rhinitis was managed mainly by GPs, who reported making the diagnosis themselves in 68 % of 
cases; rhinorrhea (64 %), sneezing (57 %) and congestion (49 %) were the symptoms most frequently taken into 
account. Limitation from AR on everyday life was rated 6.2 out of 10 by GPs. Pharmacists most often considered eye 
tearing (54 %) in their diagnosis. Almost half of GPs (49 %) and 87 % of pharmacists were unaware of the Allergic 
Rhinitis and its Impact on Asthma (ARIA) guidelines. The most commonly reported prescribed treatments by GPs 
were branded mometasone furoate, desloratadine, ebastine and generic mometasone; 21 % prescribed homeopathic 
products occasionally. On average, GPs remembered that their last patient case had moderate/severe disease, was 
prescribed anti-histamine monotherapy (37 % of cases), and did not change prescription (78 %). Pharmacists recom-
mended an antihistamine for 56 % of clients who asked for advice, and a nasal decongestant for 21 %. Patients rated 
limitation from AR on everyday life as 5.7/10. 55 % reported using multiple therapies, and 43 % were not satisfied or 
weakly satisfied with their current treatment. Patients’ main expectation for the future was to succeed in managing 
their AR symptoms (45 %), while 22 % hoped for a definitive cure. Many patients (61 %) were concerned their health 
would deteriorate.
Conclusions: Allergic rhinitis is largely managed by GPs in Italy, with pharmacists also playing a role, yet awareness 
of the ARIA guidelines among these groups is low. Patient satisfaction with treatment is moderate or low. New more 
effective treatments are needed to improve AR management in Italy. Allergy education programs need to be better 
targeted to GPs and pharmacists, and communication with patients regarding symptom control must be improved.
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Background
Allergic rhinitis (AR) is the ‘poor relation’ of the 
allergy world, firmly placed behind asthma and atopic 
dermatitis in order of importance. The burden of AR is 
often ignored, but it is associated with a significant nega-
tive impact on productivity (comparable with that of 
heart disease and diabetes) [1] and high costs; estimated 
in Italy at €210.43/patient/year, a total cost to the Italian 
economy of approximately €2.4 billion/year [2–4]. AR 
has even been associated with an increased risk of hav-
ing a road traffic accident (similar to that associated with 
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having a blood alcohol concentration of 0.05 %, the legal 
limit in many countries) [5]. The Allergic Rhinitis and its 
Impact on Asthma (ARIA) guidelines are the recognised 
worldwide authority on AR diagnosis and management 
[6, 7]. The ultimate aim of the guidelines is to achieve AR 
control. However, disease control in AR remains an elu-
sive concept, and indeed has not been fully defined.
There are several reasons why AR remains poorly con-
trolled for many patients, including the complexity of 
its underlying pathology, lack of a universally accepted 
‘control-concept’ and control language [8], a shifting 
landscape of severity [9, 10], sensitisation patterns [11, 
12] and phenotypes [13, 14], and insufficiently effective 
and fast-acting treatments [15, 16]. Currently considered 
first-line therapies (even multiple therapies) do not con-
sistently offer optimal symptomatic relief for many AR 
patients [17, 18]. Factors relating to patients and health-
care providers (HCPs) also contribute, and it is these fac-
tors that we examine in the current survey, specifically 
from the Italian viewpoint.
In Italy the prevalence of AR is high, estimated at 
18.9  % of the population and rising [2, 3]. As in most 
jurisdictions, treatment patterns may be influenced by 
reimbursement regulations. Antihistamines are reim-
bursed in all regions of Italy for chronic (>3  months) 
treatment of AR but not for on-demand therapy. Nasal 
corticosteroids are not reimbursed, except in Tuscany.
The burden of AR in Italy has been assessed in the past, 
but these surveys have focused on a particular patient 
population (e.g. children) [19] or else the data from Italy 
has been combined with that of other European countries 
[9] and the United States [20]. However, in order to assess 
the true burden of AR in Italy and describe the current AR 
landscape, a ‘360-degree’ perspective should be employed. 
Such a perspective includes the viewpoint of the general 
practitioner (GP) who diagnoses AR and prescribes medi-
cation, that of the pharmacist who dispenses medication 
and advises on AR treatments and referrals, and that of 
the patient who lives with the symptomatic burden and the 
consequences of medication and referral choices.
The aim of the current survey was to fill gaps in our 
knowledge on the burden and management of AR in 
Italy. We sought to collect a global perspective on AR 
management in Italy for the first time, by surveying GPs, 
pharmacists and patients from diagnosis to treatment 
and beyond. Specifically, the survey aimed to compose a 
picture of how AR is diagnosed and treated by GPs and 
pharmacists and to assess concerns and expectations for 
the future from the patient perspective.
Methods
Separate surveys were conducted of GPs, commu-
nity pharmacists and AR patients. Survey questions are 
listed in Additional file  1. The GP and pharmacist sur-
veys were carried out using computer-assisted telephone 
interviews, with a sample of 100 individuals from each 
category. The GPs and pharmacists participating in the 
study were randomly selected from a national database 
and were considered representative of their professional 
group working within the different geographical regions 
of Italy. Any GPs or pharmacists who had participated in 
market research within the previous 6 months were not 
enrolled. Interviews were carried out between 4th Sep-
tember 2013 and 24th September 2013.
GP survey
Information was collected on participant demographics, 
length of practice, number of patients with AR seen each 
month, practice in relation to diagnosis and referral of 
AR, symptoms considered when diagnosing AR, pathol-
ogies and comorbidities associated with AR, practice 
relating to the treatment of AR patients (including most 
frequently prescribed treatments and modalities), and 
awareness of the ARIA guidelines. GPs were also asked 
how much AR limited their patients’ everyday life (on 
a scale from 1 to 10 where 1 = not at all and 10 = very 
limiting).
Pharmacist survey
The information collected from pharmacists was simi-
lar to that described above for GPs, except that beliefs 
about underlying inflammation and relationship to 
asthma were surveyed instead of more open questions on 
pathology and comorbidity, and questions on treatment 
patterns were broken down into doctors’ prescriptions, 
cases where the patient asked for a recommendation, and 
cases where the patient chose their own treatment. Phar-
macists were not questioned on the degree of limitation 
suffered by patients.
The GP and pharmacist surveys referred to partici-
pants’ practice in general, except for a section that ques-
tioned them specifically on the last AR patient seen. This 
‘last patient case’ approach enabled more specific ques-
tions to be asked about the case severity and treatment 
approach, and was also expected to provide a greater 
degree and accuracy of memory recall.
Patient survey
Patients were recruited from multiple specialist allergy 
centres throughout Italy. Eligible patients were those 
with AR attending participating centres for the first time. 
Patients were surveyed via a self-completed written ques-
tionnaire, which was completed by a total of 552 indi-
viduals. Questions covered duration of symptoms, time 
since diagnosis, role of different categories of HCP in 
patient’s diagnosis and treatment, sources of information 
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about AR, treatments used, satisfaction with treatment, 
degree of limitation from AR in everyday life (1–10 scale 
as for GP survey), beliefs on links with other pathologies, 
chief concerns relating to AR, and expectations of future 
treatment.
Statistical analysis
Statistical analysis of responses was descriptive only, 
and presented as mean, standard deviation, median and 
range.
Results
Tables showing detailed summary statistics for the 
responses from each group (GPs, pharmacists and 
patients) are available in Additional file 2.
Participant characteristics
Participant characteristics are summarised in Table  1. 
GPs were predominantly male and of older age, with only 
10 % of respondents aged ≤50 years. Of the pharmacists, 
73 % were aged ≥50 years. The mean age of patients was 
32  years, with participants approximately equally split 
between age categories (≤20, 21–30, 31–40, over 40). The 
majority were office workers, students or unemployed.
Associated burden of AR
The average rating for limitation from AR on daily life 
given by GPs was 6.2 out of a maximum of 10, but 50 % 
gave a rating of 7 or 8 and 4  % a rating of 9 or 10. The 
average rating of limitation among patients themselves 
was slightly lower, at 5.7, but 30 % gave a rating of 7 or 8 
and 15 % a rating of 9 or 10. When GPs were asked to rate 
the severity of AR in their last patient seen (on a scale 
of 1–10 where 1 = not at all severe and 10 = extremely 
severe), the average rating was 6.03 and 38 % gave a rat-
ing of 7–8, indicating that on average the last patient seen 
had moderate-to-severe AR.
When asked to choose which of three options was their 
main concern for the future with respect to AR, 61 % of 
patients chose ‘my health getting worse’, 28 % chose ‘limi-
tations on my everyday life’, and 7 % chose ‘cost of treat-
ment’ (5  % did not record a choice). This indicates that 
AR is a source of anxiety or concern for many patients. 
Fifty-nine per cent thought that AR could lead to the 
onset of other diseases, most notably asthma, which was 
mentioned by 81  % of patients who thought other dis-
eases could develop.
Diagnosis and symptoms
In Italy, AR appears to be diagnosed and managed mainly 
by GPs (in those patients who are under medical care). 
On average GPs estimated that they made the diagnosis 
personally in 68 % of cases, referred 17 % to another doc-
tor [of whom 54 % were referred to an allergist and 39 % 
to an ear, nose and throat (ENT) specialist], and referred 
15  % to a specialist allergy centre. Most GPs said that 
some patients prefer not to go a specialist centre, mainly 
for reasons of convenience, trust in the GP or the desire 
for immediate diagnosis and treatment. Of the patients 
surveyed, 79  % said a specialist had made the diagno-
sis, which was not unexpected given that participating 
patients were all under the care of specialist centres. 
Only 30 % had independently sought information on AR 
before diagnosis. General practitioners and internet sites 
were the most frequent sources of such information.
When making the diagnosis of AR, 18  % of GPs said 
they did not use diagnostic tests. Those who did use tests 
were most likely to use total serum IgE (paper radioim-
munosorbent test; PRIST), specific serum IgE measure-
ment (radioallergosorbent test: RAST) or skin prick tests; 
usage of other tests was negligible.
The symptoms most frequently taken into account 
by GPs when diagnosing AR were nasal secretion, fits 
of sneezing and nasal obstruction. Ocular symptoms 
were given substantially less significance in the diagno-
sis (Table  2). In contrast, tearing of the eyes was con-
sidered by pharmacists as the chief symptom that made 
them suspect AR, followed by the aforementioned nasal 
Table 1 Participant characteristics
N/A not applicable
a Estimated
General practitioners (n = 100) Pharmacists (n = 100) Patients (n = 552)
Age, years
mean (SD)
57 (4.85) 55 (9.34) 32 (14.63)
Gender (% male) 75 54 52
Years of practice 78 % had ≥25 years’ practice 67 % had ≥25 years’ practice N/A
Duration of AR symptoms N/A N/A Mean (SD): 5.4 (8.19) years; 47 % were 
diagnosed with AR over 1 year ago
Mean no. of patients (SD)a 1287 (316) registered 3227 (2272) seen/month N/A
Mean no. of patients with ARa 46 seen/month 20 % (17.95) of pts have AR N/A
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symptoms. They also cited tearing of the eyes as the most 
frequent symptom seen in the AR patients who consulted 
them. The same nasal symptoms mentioned by GPs were 
also most frequently mentioned by patients when asked 
which symptoms of AR they first experienced. Patients 
mentioned ocular symptoms less frequently than nasal 
symptoms.
Asthma was by far the most likely comorbidity to be 
taken into account by GPs when diagnosing AR. Of phar-
macists, 8 out of 10 believed that AR is associated with 
underlying inflammation, and three-quarters believed 
that AR can cause asthma if not treated in a timely 
manner.
Treatment decision‑making
The GPs estimated that for 69  % of their patients they 
decided on the treatment themselves, while a specialist 
decided the treatment for 20 % and an allergy centre for 
11 %. The average duration of a consultation in which a 
treatment was formulated for the first time was 16 min, 
while consultation times for patients whose treatment 
was already formulated were reduced to 9 min on aver-
age. In consultations involving new treatments, an aver-
age of 38 % of the time was spent framing the pathology, 
23  % was spent detailing the administration method, 
21  % giving reasons for proper treatment compliance, 
and 18 % educating the patient about any risk linked to 
comorbidity.
Of the patients, just over half had their current treat-
ment prescribed by a specialist (again, to be expected 
given the population surveyed) and a third were using 
treatment prescribed by a GP. Only 4 % had their treat-
ment recommended by a pharmacist and 4  % had cho-
sen their own. However, pharmacists appear to play 
an important role in treatment decisions in the wider 
patient population: pharmacist respondents estimated 
that a third of patients they saw asked the pharmacist 
for a treatment recommendation. A quarter asked for a 
specific treatment without a prescription, and 40 % pre-
sented a doctor’s prescription.
Treatment patterns
Almost half of GPs (49 %) and the great majority of phar-
macists (87  %) were unaware of the ARIA guidelines 
(Fig. 1). Of all treatments prescribed by GPs, 57 % were 
oral medications and 46 % nasal medications. About half 
were ongoing treatments and half were for use as needed. 
When asked which three products they prescribed most 
frequently for AR, GPs mentioned branded mometasone 
furoate most frequently, followed by desloratadine, ebas-
tine and generic mometasone (Fig.  2). Antihistamines 
were mentioned more frequently than intranasal steroids 
(INSs). Twenty-one percent of GPs said they sometimes 
prescribed homeopathic products.
For the ‘last patient’ case, which had moderate-to-
severe AR on average, 37 % of GPs reported prescribing 
antihistamine alone and 27  % prescribed two products, 
most commonly an antihistamine and an INS (Fig. 3). For 
‘last patient’ cases who were already on treatment, GPs 
reported that in 78  % of cases they did not change the 
Table 2 Symptoms considered by GPs and pharmacists when diagnosing AR, and symptoms first experienced by patients
Symptom % citing as chief symptom Total number of mentions Symptoms at 1st  
emergence of AR (% citing)
GPs Pharmacists GPs Pharmacists Patients
Nasal symptoms
 Nasal secretion 28 12 64 35 68
 Fits of sneezing 28 24 57 41 73
 Nasal obstruction 22 19 49 38 63
 Itchy nose 7 9 36 29 56
 Rhinorrhoea 1 5 7 8 –
Ocular symptoms
 Tearing 8 19 42 54 55
 Redness of eyes – 9 20 29 49
 Conjunctivitis – 4 – –
Other symptoms
 Cough 1 7 3 25
 Itchy palate – 2 8 11 33
 Headache – 3 –
 Respiratory problems – 1 – 4 –
 Other 2 2 4 4
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prescription, which was an antihistamine in the majority 
of cases.
The pharmacist and patient surveys provided addi-
tional perspectives on treatment patterns. Pharmacists 
reported recommending an antihistamine for most cases 
(56  %) who asked for a recommendation, followed by a 
vasoconstrictor (21  %), homeopathic therapy (12  %) or 
an intranasal/oral corticosteroid (12  %). They estimated 
that 55 % of doctors’ prescriptions they dealt with were 
for antihistamines, 37 % for intranasal or oral corticoster-
oids, and 15 % for vasoconstrictors. Half of independent 
requests by patients were estimated to be for antihista-
mines, and a quarter each for INS and vasoconstrictors. 
These trends were broadly reflected in the ‘last patient’ 
case responses (data not shown).
When patients were asked what products they currently 
used to control their AR, 69 % said they used an antihis-
tamine and 25  % an INS, which was in agreement with 
the GP and pharmacist surveys. However, only 4 % used 
vasoconstrictors and 3 % homeopathy. Nine per cent used 
other remedies and 17  % were not using any treatment. 
A quarter said they would consider using homeopathy. 
On average, patients were using 1.7 products, and 55  % 
reported using multiple therapies (Fig. 4). The most com-
mon combination was an antihistamine and an INS.
Satisfaction with treatment
Just over 40  % of patients were either not satisfied or 
weakly satisfied with their current treatment (satisfac-
tion rating of ≤6 out of 10), with an average rating of 6.47 
(Fig. 5). Satisfaction with the way healthcare profession-
als had managed their AR to date was somewhat higher 
(average rating 7.25). Patients’ main expectation for the 
future was to succeed in managing or easing their AR 
symptoms (45 %), while 22 % hoped for a definitive cure.
Discussion
This survey details for the first time the practices of GPs 
and pharmacists in relation to diagnosis and treatment of 
Fig. 1 Awareness of the ARIA guidelines among GPs and pharmacists
Fig. 2 Most frequent prescribing by GPs (% mentioning product in 
their 3 most frequently prescribed treatments). ‘First mention’ denotes 
percentage who mentioned it as the product they most frequently 
prescribe; ‘other mentions’ denotes percentage mentioning the prod-
uct as being one of the three they prescribe most frequently
Fig. 3 Prescribing by GPs for last AR patient seen (% prescribing 
product)
Fig. 4 Proportion of patients using multiple therapies
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AR in Italy. It also gives significant insight into patients’ 
behaviours and attitudes to this prevalent condition and 
its treatment.
Allergic rhinitis is on the increase [21] and becom-
ing ever more challenging to treat so it is more impor-
tant than ever that HCPs have the most up-to-date 
evidence on the best treatments. The ARIA guidelines 
[7] set out evidence-based standards of best practice 
for diagnosis and treatment of AR. However, the cur-
rent survey suggested that only half of GPs in Italy 
are aware of these guidelines, despite seeing an aver-
age of 46 AR patients a month. Awareness is even 
lower among community pharmacists, at just 13  %, 
even though participating pharmacists estimated that 
20 % of their clients had AR. There are specific ARIA 
guidelines for pharmacists detailing all aspects of AR 
diagnosis and treatment, with advice given on when 
referral to a physician is appropriate [22]. Clearly, 
more needs to be done to make HCPs aware of the 
guidelines for diagnosing and treating this extremely 
common condition.
Allergic Rhinitis and its Impact on Asthma recom-
mends that patients who present with two or more symp-
toms of AR (rhinorrhoea, sneezing, nasal obstruction/
pruritus ±  conjunctivitis) for >1  h a day, and who have 
a positive allergen test, should be referred to a special-
ist for diagnosis and disease classification (e.g. inter-
mittent, persistent, non-allergic) [6, 23]. However, the 
survey showed that in Italy it is GPs, not allergy special-
ists, who are making the majority of AR diagnoses and 
formulating the treatment plan, either when the patient 
presents directly or is referred by a pharmacist. Only a 
third of patients presenting to GPs with possible AR were 
referred to specialist doctor or allergy centres. One rea-
son for this referral deficit is that some patients prefer the 
convenience and immediacy of diagnosis and treatment 
by their GP and do not wish to visit a specialist.
With regard to treatment, the ARIA algorithm recom-
mends a step-up, step-down approach depending on 
whether the symptoms are intermittent or persistent. 
Antihistamines and leukotriene-receptor antagonists 
(LTRA) are recommended as first-line for patients with 
mild symptoms, while INSs are considered first-line for 
patients with moderate-to-severe AR [7, 23]. This sur-
vey revealed a significant mismatch between treatment 
patterns among Italian GPs and pharmacists and the 
ARIA recommendations. GPs perceived that the average 
patient presenting to them had moderate-to-severe AR, 
yet the most frequently prescribed AR treatment was an 
antihistamine alone, which is not concordant with the 
ARIA guidelines. Judging by the fact that 69 % of patients 
reported using an antihistamine and 25  % an INS, and 
just over half said their treatment had been prescribed by 
a specialist, there also appears to be some deviation from 
the ARIA guidelines among specialists, although the pre-
scribing patterns of specialists were not surveyed directly, 
and neither was the AR severity of the patients. There was 
also a reluctance by GPs to change AR treatment even if 
the patient had moderate-to-severe symptoms remain-
ing. This may reflect the fact that oral antihistamines are 
reimbursed for chronic AR throughout Italy, whereas only 
one region (Tuscany) currently reimburses nasal corticos-
teroids. Nasal antihistamines are not reimbursed so are 
not widely used in Italy. Pharmacists too recommended 
antihistamines most frequently, although this may reflect 
a milder degree of symptoms in those patients seeking 
treatment without a doctor’s prescription. There was also 
some confusion among pharmacists about the princi-
pal symptoms of AR. Eye watering was cited above nasal 
symptoms as the main symptom leading to suspicion of 
AR, even though it is not classified as a major indicator 
of AR in the guidelines. Pharmacists reported that they 
referred just under half of patients to a doctor.
Despite reporting satisfaction with the management of 
their AR by doctors and pharmacists, patients in Italy are 
less happy with AR treatments. The average satisfaction 
rating was reported as 6.4 out of 10, with 43 % of patients 
reporting a rating of 6 or below. One reason for the low 
satisfaction may be the knowledge base from which GPs 
and pharmacists are working, and therefore prescribing. 
However, AR is known to be a difficult condition to treat. 
It is likely that patients’ dissatisfaction also stems from 
the therapeutic deficits of commonly prescribed thera-
pies; participating patients were using an average of 1.7 
therapies and 55  % of patients were on more than one 
treatment. Adding an oral antihistamine or LTRA to an 
INS is neither officially recommended by the guidelines 
[7] nor is it supported by the scientific evidence [24, 25].
Fig. 5 Patient satisfaction with current AR treatment
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Patients have a significant impact on their own AR 
management. Many AR medications are over the coun-
ter and patients frequently self-diagnose. Pharmacists 
reported that 1 in 4 patients asked for a specific treat-
ment, and that it was most often an antihistamine. 
Patients also decide whether or not to adhere to pre-
scribed medication. Perhaps surprisingly, GPs and phar-
macists on average perceived a slightly greater degree 
of limitation to daily life from AR symptoms than was 
reported by patients themselves, even though the patients 
recruited were under the care of specialist centres. This 
suggests that failure by HCPs to take AR seriously is not 
a major issue in Italy. However, 15  % of patients gave a 
limitation rating of 9 or 10, showing that for a minority 
of sufferers AR imposes a very severe limitation on eve-
ryday activities.
What can be done to improve the management of AR 
in Italy and elsewhere? It is clear that a greater awareness 
of formal guidelines for treatment would be beneficial for 
all parties. It would enable GPs to assess disease severity 
with greater accuracy and to prescribe the most effective 
treatment options for individual patients. For pharma-
cists, it is important to be able to accurately recognise AR 
and assess its severity, and make a guideline-informed 
treatment recommendation, whether it is medication or 
referral to a physician.
To close the gap between current practices and the 
most up-to-date evidence-based treatment strategies, 
allergy societies and guidelines need to adapt to the real-
ity that AR is diagnosed and managed by generalist phy-
sicians in the majority of cases. Assessment of AR needs 
to be standardised and simplified, for example by using 
a visual analogue scale (VAS). This would likely lead to 
improved prescribing for moderate-to-severe disease. 
Patients on multiple therapies and those whose symp-
toms are insufficiently controlled on INS or intranasal 
antihistamine monotherapy could benefit from increased 
awareness of new and more effective AR treatments, 
which could potentially increase treatment satisfaction 
through improved convenience and more efficient drug 
delivery [26]. For example, an advanced intranasal deliv-
ery system of azelastine hydrochloride and fluticasone 
propionate (Dymista®, Meda, Solna, Sweden) is now 
available in Italy which is twice as effective as an INS 
and provides rapid symptom control in real-life [27–31]. 
Improved communication between HCPs and patients 
regarding degree of symptom control is also needed, so 
that GPs can more easily recognise dissatisfaction with 
treatment and are encouraged to change a patients’ treat-
ment if it is not providing adequate control. Progress is 
being made in this direction: for example, ARIA in col-
laboration with MACVIA-LR (a reference site of the 
European Innovation Partnership on Active and Health 
Aging) is currently developing a digital VAS-based app 
for patients to document AR symptom control on ther-
apy [32]. Companion apps for pharmacists and GPs are 
also planned with the aim of introducing a common lan-
guage of AR control for all stakeholders and ultimately 
improving inter-discipline and patient communication 
and the way AR is assessed and treated.
Conclusion
Allergic rhinitis is largely managed by GPs in Italy. Phar-
macists are also important, acting as gatekeepers to treat-
ment. Awareness of the ARIA guidelines among GPs and 
pharmacists is low, and treatment is not always in accord-
ance with evidence-based best practice. Patient satisfac-
tion with treatment is moderate or low. Allergy education 
programs need to be targeted at GPs and pharmacists, 
and communication with patients regarding symptom 
control needs to be improved.
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